Comparison of the duration of androgen deprivation therapy in prostate cancer-RADICALS-HD trial

Comparison of the duration of androgen deprivation therapy in prostate cancer-RADICALS-HD trial

Saved in:

Bibliographic Details
Main Author:	Prabhu E. Rajendran
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-01-01
Series:	Indian Journal of Urology
Online Access:	https://journals.lww.com/10.4103/iju.iju_347_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

Metabolic changes in patients with prostate cancer with androgen deprivation therapy
by: Maxim N. Peshkov, et al.
Published: (2020-06-01)

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
by: Allison B. Reiss, et al.
Published: (2024-10-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
by: Safae Terrisse, et al.
Published: (2022-11-01)

Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy
by: S. P. Mironov, et al.
Published: (2021-09-01)

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
by: Jennifer Dunsmore, et al.
Published: (2024-09-01)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
by: Tyler Etheridge, et al.
Published: (2019-01-01)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
by: Chi-Ho Lee, et al.
Published: (2017-01-01)

Microbial Endocrinology Redefines Prostate Cancer - The Bugs That Outwit Androgen Deprivation
by: Mohammad Asim
Published: (2025-07-01)

Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer
by: Christopher J. D. Wallis, et al.
Published: (2024-01-01)

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
by: Hang Phuong Pham, et al.
Published: (2022-03-01)

Thresholds of Body Composition Changes Associated with Survival During Androgen Deprivation Therapy in Prostate Cancer
by: Pin-Chi Chen, et al.
Published: (2024-12-01)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
by: Katherine Neubecker, et al.
Published: (2011-01-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
by: Bhavin R. Shastri, et al.
Published: (2011-01-01)

Androgen Deprivation Therapy–Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients
by: Jie Lee, et al.
Published: (2025-06-01)

Case Report: Surgical androgen deprivation therapy for prostate cancer in a patient with concurrent scrotal paget’s disease
by: Sinan Yang, et al.
Published: (2025-06-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges
by: Ursula Vogl
Published: (2024-06-01)

Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
by: Ze Wang, et al.
Published: (2025-08-01)

Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer
by: Kaleem Atchia, et al.
Published: (2022-03-01)

Modeling the Effects of Chemotherapeutic Dose Response on a Stochastic Tumor-Immune Model of Prostate Cancer with Androgen Deprivation Therapy
by: Lin Chen, et al.
Published: (2023-01-01)

Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis
by: Malin Hagberg Thulin, et al.
Published: (2025-06-01)

Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system
by: Chun-Li Wang, et al.
Published: (2024-11-01)

Fasting Blood Glucose and Lipid Profile Alterations following Twelve-Month Androgen Deprivation Therapy in Men with Prostate Cancer
by: Hasan S. Sağlam, et al.
Published: (2012-01-01)

Feasibility and safety of physical exercise in men with prostate cancer receiving androgen deprivation therapy and radiotherapy: a study protocol
by: Stefania Fugazzaro, et al.
Published: (2022-03-01)

Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance
by: Guang Peng, et al.
Published: (2023-12-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

Intermittent androgen therapy in prostate cancer reveals the pro-apoptotic roles of androgen/androgen receptor: an overview
by: Saleh Altuwaijri, et al.
Published: (2025-03-01)

Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model
by: Shengchao Zhao, et al.
Published: (2025-06-01)

Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study)
by: Robert U Newton, et al.
Published: (2024-03-01)

5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
by: Qianxia Li, et al.
Published: (2025-03-01)

Androgen deprivation therapy and hormonal status in men with COVID-19
by: A. A. Kamalov, et al.
Published: (2023-01-01)

A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer
by: M. Shanmugavalli, et al.
Published: (2025-07-01)

Evaluating the Effects of Prostate Radiotherapy Intensified with Pelvic Nodal Radiotherapy and Androgen Deprivation Therapy on Myelosuppression: Single-Institution Experience
by: Yousef Katib, et al.
Published: (2024-09-01)

Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: a randomised, double-blind, placebo-controlled trial
by: Robert U Newton, et al.
Published: (2019-09-01)